Clinical trial results for
previously treated
advanced esophageal
squamous cell cancer
For people with previously treated advanced
esophageal squamous cell cancer
Clinical trial results for
previously treated
advanced esophageal
squamous cell cancer
For people with previously treated advanced
esophageal squamous cell cancer
Actor portrayal.
In a clinical trial of 419 people with advanced esophageal squamous cell cancer that had been previously treated with fluoropyrimidine- and platinum-based chemotherapy, 210 people were given OPDIVO and 209 people were given either docetaxel or paclitaxel chemotherapy.
Half the people were alive
Half the people were alive
In the clinical trial, people given OPDIVO had a 23% lower risk of dying than those given docetaxel or paclitaxel chemotherapy.
There was no significant difference between the two treatments in the percentage of patients who responded to treatment and in the length of time that patients lived without their tumors worsening.
OPDIVO will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with previously treated advanced esophageal squamous cell cancer
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.